XableCath Receives FDA Clearance for Broadly Effective Catheter Aimed at Peripheral Arterial Disease
XableCath, a clinical stage medical device company, announced its XableCath blunt tip support catheter has received clearance from the U.S. Food and Drug Administration. The blunt tip catheter facilitates true lumen passage of lesions, both above and below the knee, in the peripheral vasculature. Procedures using the XableCath blunt tip catheters can be performed quickly and safely, allowing physicians to more effectively treat peripheral arterial disease (PAD). “In two clini
Q Therapeutics Announces Research Collaboration With REPROCELL
SALT LAKE CITY and YOKOHAMA, Japan, Dec. 13, 2017 (GLOBE NEWSWIRE) -- Q Therapeutics, Inc., a developer of clinical-stage cell therapies for central nervous system (CNS) disease and injury, announced a collaborative research agreement with REPROCELL Inc. that combines each company’s proprietary technologies to develop new iPS cell (IPSC) therapies for central nervous system (CNS) diseases. Q Therapeutics has patented a process to manufacture glial-restricted progenitor (GRP)